A clinical trial involving leptin was updated on August 21, 2026. The study, registered as NCT06536881 and titled "Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming," is listed with a status of recruiting.
The trial does not have an assigned phase, with the phase field listed as NA. No results have been posted for this study as of the update date.
This update reflects only the recruitment status as recorded on ClinicalTrials.gov. No outcome data, safety findings, or efficacy conclusions are included in this record. Readers should not infer any results or interpretations beyond the recruiting status noted here.
Leptin remains an approved compound. This trial update is procedural in nature, confirming that the study is currently open for participant enrollment rather than reporting any findings.
For more background on leptin, readers can consult the compound overview.